Polymorphism in the Cholesterol 24S-Hydroxylase Gene (CYP46A1) Associated with the APOEυ3 Allele Increases the Risk of Alzheimer’s Disease and of Mild Cognitive Impairment Progressing to Alzheimer’s Disease | Zendy

Valentina Fernández del Pozo | Zendy; Maite Álvarez Álvarez | Zendy; Manuel Fernández Martínez | Zendy; L. Galdós Alcelay | Zendy; Fernando Gómez Busto | Zendy; J.A. Peña | Zendy; Miguel Á. AlfonsoSánchez | Zendy; Juan José Zarranz Imirizaldu | Zendy; Marian M. de Pancorbo | Zendy

Open Access

Polymorphism in the Cholesterol 24S-Hydroxylase Gene (CYP46A1) Associated with the APOEυ3 Allele Increases the Risk of Alzheimer’s Disease and of Mild Cognitive Impairment Progressing to Alzheimer’s Disease

Author(s) -

Valentina Fernández del Pozo,

Maite Álvarez Álvarez,

Manuel Fernández Martínez,

L. Galdós Alcelay,

Fernando Gómez Busto,

J.A. Peña,

Miguel Á. AlfonsoSánchez,

Juan José Zarranz Imirizaldu,

Marian M. de Pancorbo

Publication year - 2005

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000090215

Subject(s) - allele , apolipoprotein e , alzheimer's disease , medicine , genotype , disease , risk factor , cholesterol , polymorphism (computer science) , endocrinology , allele frequency , genetics , psychology , biology , gene

Late-onset Alzheimer's disease (LOAD) is associated with changes in certain proteins, such as ApoE and Cyp46A1, of the elimination route for cerebral cholesterol. The main lipoprotein involved in its transport is ApoE whose Epsilon4 allele is the least efficient. However, the presence or absence of this allele does not determine the development of LOAD, which implies the existence of other susceptibility factors associated with the disease, such as the CYP46A1 gene that encodes the enzyme cholesterol 24S-hydroxylase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research